Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All casirivimab/imdevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 24% Improvement Relative Risk Casirivimab/i..  Osugi et al.  EARLY TREATMENT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Retrospective 104 patients in Japan (August - September 2021) Study underpowered to detect differences c19early.org Osugi et al., Cureus, February 2022 Favors casirivimab/im.. Favors control

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan

Osugi et al., Cureus, doi:10.7759/cureus.21882
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
16th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.000018 from 28 studies, recognized in 42 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 104 outpatients in Japan, 30 treated with casirivimab/imdevimab, showing no significant difference in hospitalization.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants Haars, Liu, Pochtovyi, Sheward, Tatham, VanBlargan.
risk of hospitalization, 24.0% lower, HR 0.76, p = 0.65, treatment 4 of 30 (13.3%), control 15 of 74 (20.3%), adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Osugi et al., 3 Feb 2022, retrospective, Japan, peer-reviewed, mean age 47.8, 5 authors, study period 31 August, 2021 - 27 September, 2021.
This PaperCasirivimab/i..All
Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Yasuhiro Osugi, Hitoshi Iwata, Yasushi Imai, Daiki Kobayashi, Ryutaro Hirashima
Cureus, doi:10.7759/cureus.21882
Aim: This study aimed to report clinical courses of patients who had mild coronavirus disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab/imdevimab in Japan, where mortality and number of severe patients were very limited compared to other resource-rich countries.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. The Ethical Committee of Toyota Regional Medical Center issued approval #2021-kenrin13. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Arentz, Yim, Klaff, Lokhandwala, Riedo et al., Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state, JAMA, doi:10.1001/jama.2020.4326
Dougan, Nirula, Azizad, Bamlanivimab plus etesevimab in mild or moderate COVID-19, N Engl J Med, doi:10.1056/NEJMoa2102685
Gupta, Gonzalez-Rojas, Juarez, Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med, doi:10.1056/NEJMoa2107934
Liu, Fang, Deng, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province, Chin Med J (Engl), doi:10.1097/CM9.0000000000000744
Osugi, None, Cureus, doi:10.7759/cureus.218825of5
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody combination and outcomes in outpatients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2108163
{ 'DOI': '10.7759/cureus.21882', 'ISSN': ['2168-8184'], 'URL': 'http://dx.doi.org/10.7759/cureus.21882', 'author': [ {'affiliation': [], 'family': 'Osugi', 'given': 'Yasuhiro', 'sequence': 'first'}, {'affiliation': [], 'family': 'Iwata', 'given': 'Hitoshi', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Imai', 'given': 'Yasushi', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kobayashi', 'given': 'Daiki', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Hirashima', 'given': 'Ryutaro', 'sequence': 'additional'}], 'container-title': ['Cureus'], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 2, 3]], 'date-time': '2022-02-03T20:28:16Z', 'timestamp': 1643920096000}, 'deposited': { 'date-parts': [[2022, 2, 3]], 'date-time': '2022-02-03T20:28:20Z', 'timestamp': 1643920100000}, 'indexed': {'date-parts': [[2022, 2, 5]], 'date-time': '2022-02-05T03:14:52Z', 'timestamp': 1644030892122}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'print', 'value': '2168-8184'}], 'issued': {'date-parts': [[2022, 2, 3]]}, 'language': 'en', 'link': [ { 'URL': 'https://www.cureus.com/articles/83767-clinical-prognosis-of-patients-with-mild-covid-19-treated-with-casirivimabimdevimab-in-japan', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '4492', 'original-title': [], 'prefix': '10.7759', 'published': {'date-parts': [[2022, 2, 3]]}, 'published-print': {'date-parts': [[2022, 2, 3]]}, 'publisher': 'Cureus, Inc.', 'reference': [ { 'DOI': '10.1056/NEJMoa2108163', 'article-title': 'REGEN-COV antibody combination and outcomes in outpatients with ' 'COVID-19', 'author': 'Weinreich DM', 'doi-asserted-by': 'publisher', 'journal-title': 'N Engl J Med', 'key': 'ref1', 'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, et al.. REGEN-COV antibody ' 'combination and outcomes in outpatients with COVID-19. N Engl J Med. ' '2021, 385:10.1056/NEJMoa2108163', 'volume': '385', 'year': '2021'}, { 'key': 'ref2', 'unstructured': 'Japan becomes first country to approve Regeneron antibody cocktail ' '(casirivimab and imdevimab) for the treatment of mild to moderate ' 'COVID-19. (2021). Accessed. January 16, 2022: ' 'https://newsroom.regeneron.com/news-releases/news-release-details/japan-becomes-first-country-approve-regeneron-antib....'}, { 'key': 'ref3', 'unstructured': 'WHO coronavirus (COVID-19) dashboard. (2022). Accessed. January 12, ' '2022: https://covid19.who.int/.'}, { 'key': 'ref4', 'unstructured': 'Underlying medical conditions associated with higher risk for severe ' 'COVID-19. information for healthcare providers. (2021). Accessed: ' 'January 12, 2022: ' 'https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.'}, { 'DOI': '10.1097/CM9.0000000000000744', 'article-title': 'Clinical characteristics of novel coronavirus cases in tertiary ' 'hospitals in Hubei province', 'author': 'Liu K', 'doi-asserted-by': 'publisher', 'journal-title': 'Chin Med J (Engl)', 'key': 'ref5', 'unstructured': 'Liu K, Fang YY, Deng Y, et al.. Clinical characteristics of novel ' 'coronavirus cases in tertiary hospitals in Hubei province. Chin Med J ' '(Engl). 2020, 133:1025-31. 10.1097/CM9.0000000000000744', 'volume': '133', 'year': '2020'}, { 'DOI': '10.15585/mmwr.mm6912e2', 'doi-asserted-by': 'crossref', 'key': 'ref6', 'unstructured': 'Severe outcomes among patients with coronavirus disease 2019 (COVID-19) ' '- United States, February 12-March 16, 2020. (2020). Accessed. January ' '16, 2022: https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm.'}, { 'DOI': '10.1001/jama.2020.4326', 'article-title': 'Characteristics and outcomes of 21 critically Ill patients with ' 'COVID-19 in Washington state', 'author': 'Arentz M', 'doi-asserted-by': 'publisher', 'journal-title': 'JAMA', 'key': 'ref7', 'unstructured': 'Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. ' 'Characteristics and outcomes of 21 critically Ill patients with COVID-19 ' 'in Washington state. JAMA. 2020, 323:1612-4. 10.1001/jama.2020.4326', 'volume': '323', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2107934', 'article-title': 'Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody ' 'sotrovimab', 'author': 'Gupta A', 'doi-asserted-by': 'publisher', 'journal-title': 'N Engl J Med', 'key': 'ref8', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al.. Early treatment for ' 'COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. ' '2021, 385:1941-50. 10.1056/NEJMoa2107934', 'volume': '385', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2102685', 'article-title': 'Bamlanivimab plus etesevimab in mild or moderate COVID-19', 'author': 'Dougan M', 'doi-asserted-by': 'publisher', 'journal-title': 'N Engl J Med', 'key': 'ref9', 'unstructured': 'Dougan M, Nirula A, Azizad M, et al.. Bamlanivimab plus etesevimab in ' 'mild or moderate COVID-19. N Engl J Med. 2021, 385:1382-92. ' '10.1056/NEJMoa2102685', 'volume': '385', 'year': '2021'}, { 'key': 'ref10', 'unstructured': 'Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 ' 'variant of concern (Omicron) for the EU/EEA. (2021). Accessed. January ' '16, 2022: ' 'https://www.ecdc.europa.eu/sites/default/files/documents/Implications-emergence-spread-SARS-CoV-2%20B.1.1.529-variant....'}, { 'key': 'ref11', 'unstructured': 'Enhancing response to Omicron SARS-CoV-2 variant. (2022). Accessed. ' 'January 16, 2022: ' 'https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-acti....'}], 'reference-count': 11, 'references-count': 11, 'relation': {}, 'score': 1, 'short-container-title': [], 'short-title': [], 'source': 'Crossref', 'subject': ['Aerospace Engineering'], 'subtitle': [], 'title': ['Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan'], 'type': 'journal-article'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit